Reykjavik/Isafjordur, Iceland, June 20, 2011 — Kerecis Limited, the emerging tissue-regeneration company, today announced that its founder and CEO G. Fertram Sigurjonsson will make a presentation at Elsevier’s IN3 East Investor Conference in Boston (Wednesday, June 22, 8:35 a.m., Hyatt Regency Boston).
Kerecis, which recently raised $ 1 million interim financing, is looking to close up to USD $4.3 million by the last quarter of 2011. The money would be used to complete clinical trials of its patent-pending, marine-derived, tissue-regeneration product, which has applications across multiple medical-device sectors including wound care and abdominal wall reconstruction.
Statistics show a large need for wound care. Each year about 6 million Americans suffer from problem wounds caused by diabetes, circulatory problems and other conditions, with 1.1 to 1.8 million new cases added each year.
More than 20 million Americans have diabetes, almost 20 percent of whom are over the age of 60. 15 percent of all diabetics will develop problem wounds, and about 82,000 diabetics undergo amputation each year because of such wounds.
G. Fertram Sigurjonsson, Kerecis Founder and CEO:
“At the In3 East conference we will be updating the investor community about the progress of our business plan to encourage additional investor and potential partner interest in our programs. The clinical development program for our first applications in the chronic wound area continue with great success and we are about to embark on new multi-center trials in the US, which will greatly improve the level of clinical data for our technology”